

*patients and their families to enhance the quality of life.*

*f*

**FOR IMMEDIATE RELEASE**

No. 10-06

February 24, 2010

Eisai Co., Ltd.

**Eisai Launches REVOVIR<sup>®</sup> in the Philippines for the Treatment of Chronic Hepatitis B**

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that the Company's Philippine subsidiary, HI-Eisai Pharmaceutical Inc. (Headquarters: Makati City, the Philippines, President: Lourdes Magno), launched "REVOVIR<sup>®</sup> 30mg Capsules" (generic name: clevudine) in the Philippines for the treatment of chronic hepatitis B.

REVOVIR<sup>®</sup> is a Nucleoside Reverse Transcriptase Inhibitor (NRTI). It exerts anti-hepatitis B virus (HBV) effects by inhibiting DNA polymerase, the enzyme that is necessary for the virus to replicate. Clinical studies have shown that a once-daily oral dose of REVOVIR<sup>®</sup>

Eisai considers hepatic disease as a therapeutic area of focus in China and other Asian countries and thus markets and develops drugs such as hepatic disease/allergic disease agents Stronger Neo-Minophagen C<sup>®</sup> and Glycyron<sup>®</sup> Tablets as well as branched-chain amino acid formula Livact<sup>®</sup> Granules. Through these efforts, Eisai will continue to make further contributions to increasing the benefits to patients with hepatic disease across Asia.

**[Please refer to the following notes for information on HI-Eisai Pharmaceutical Inc. and the product]**

Contacts:

Eisai Co., Ltd.

Public Relations Department

Tel. +81-(0)3-3817-5120

<Notes to Editors>

**About HI-Eisai Pharmaceutical Inc.**

Corporate Name: HI-Eisai Pharmaceutical Inc.  
Location: Makati City, the Philippines  
Date of Establishment: July 1974  
Paid-in Capital: 56,250 Thousand Philippine Pesos (as of December 31, 2009)  
Scope of Business: Manufacture and Marketing of pharmaceutical products  
President: Lourdes Magno

**About REVOVIR®**

Product Name: Revovir®  
Generic Name: clevudine  
Formulation: Capsule (30mg)  
Indication: Inhibition of virus replication in chronic hepatitis B patients (HBeAg-positive or HBeAg-negative) with evidence of active viral replication and elevations in serum aminotransferases (ALT or AST)  
Dosage and Administration: The usual adult dose for oral use is 1 capsule (30mg of clevudine) once daily or as prescribed by the physician.

**Eight Eisai Licensed Territories for Clevudine**

China, India, Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam